SWITCHING FROM DOUBLE-BLIND ENTACAPONE OR PLACEBO TO OPEN-LABEL OPICAPONE: NMSS RESULTS (1-YEAR EXTENSION BIPARK-I STUDY)

被引：0
|
作者：
Fabregues, O. [1 ]
Tolosa, E. [2 ]
Ferreira, J. [3 ]
Lees, A. [4 ]
Santos, A. [5 ]
Rocha, J. [6 ]
Soares-Da-Silva, P. [5 ]
机构：
[1] Univ Hosp Vall dHebron, Barcelona, Spain
[2] Hosp Clin Univ Barcelona, Barcelona, Spain
[3] Inst Med Mol, Neurol Clin Res Unit, Lisbon, Portugal
[4] Natl Hosp Neurol & Neurosurg, London, England
[5] BIAL Portela & Co SA, Global Parkinson Dis, Sao Mamede do Coronado, Portugal
[6] BIAL Portela & Co SA, Res & Dev, Sao Mamede do Coronado, Portugal
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 2019年 / 90卷 / 12期
关键词：
D O I：
10.1136/jnnp-2019-ABN-2.133
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
141
引用
收藏
页码：E49 / E49
页数：1
相关论文
共 50 条
  • [41] Efficacy of opicapone in Parkinson's disease patients with 'early' motor fluctuations: Patient and clinical global impression of change from the BIPARK-I double-blind experience
    Rocha, F.
    Stocchi, F.
    Lees, A.
    Ferreira, J.
    Poewe, W.
    Rascol, O.
    Santos, A.
    Magalhaes, D.
    Soares-da-Silva, P.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [42] Patients' experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study
    Haas, Julia W.
    Ongaro, Giulio
    Jacobson, Eric
    Conboy, Lisa A.
    Nee, Judy
    Iturrino, Johanna
    Rangan, Vikram
    Lembo, Anthony
    Kaptchuk, Ted J.
    Ballou, Sarah
    BMC PSYCHOLOGY, 2022, 10 (01)
  • [43] Patients’ experiences treated with open-label placebo versus double-blind placebo: a mixed methods qualitative study
    Julia W. Haas
    Giulio Ongaro
    Eric Jacobson
    Lisa A. Conboy
    Judy Nee
    Johanna Iturrino
    Vikram Rangan
    Anthony Lembo
    Ted J. Kaptchuk
    Sarah Ballou
    BMC Psychology, 10
  • [44] An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson's disease -Comfort-PD study part 2
    Takeda, A.
    Takahashi, R.
    Tsuboi, Y.
    Nomoto, M.
    Maeda, T.
    Nishimura, A.
    Hattori, N.
    MOVEMENT DISORDERS, 2019, 34 : S88 - S89
  • [45] Itopride in functional dyspepsia: open-label, 1-year treatment follow-up of two multicenter, randomized, double-blind, placebo-controlled trials
    Broeders, Bert
    Tack, Jan
    Talley, Nicholas J.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2025, 18
  • [46] Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia
    Najarian, Dean
    Turkoz, Ibrahim
    Knight, R. Karl
    Galderisi, Silvana
    Lamaison, Hector F.
    Zalitacz, Piotr
    Aravind, Suresh
    Richarz, Ute
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2023, : 537 - 544
  • [47] Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study
    Wada, Takashi
    Inagaki, Masaya
    Yoshinari, Toru
    Terata, Ryuji
    Totsuka, Naoko
    Gotou, Miki
    Hashimoto, Gaia
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (02) : 120 - 130
  • [48] LANADELUMAB EFFICACY AFTER SWITCHING FROM PLACEBO: RESULTS FROM THE HELP AND HELP OPEN-LABEL EXTENSION STUDIES
    Tachdjian, R.
    Anderson, J.
    Busse, P.
    Johnston, D.
    Kiani, S.
    Nurse, C.
    Paes, K.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S38 - S38
  • [49] Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study
    Chung, Lorinda
    Silver, Richard M.
    Steen, Virginia
    Furst, Daniel E.
    Castelino, Flavia, V
    Trojanowski, Marcin
    Spiera, Robert
    Domsic, Robyn
    Rodriguez-Pla, Alicia
    Katsumoto, Tamiko R.
    Goulaouic, Helene
    Wang, Hong
    Espinasse, Melanie
    El-Chemaly, Souheil
    Wang, Rui
    RHEUMATOLOGY, 2025,
  • [50] Efficacy and Tolerability of Elamipretide in Patients With Barth Syndrome: Results From Tazpower, a Randomized, Double-Blind, Placebo-Controlled, Crossover and Open-Label Extension Trial
    Vernon, Hilary J.
    Thompson, WIlliam R.
    Aiudi, Anthony
    Jones, John J.
    Carr, Jim
    Hornby, Brittany DeCroes
    CIRCULATION, 2019, 140
12345